secwatch.observer — SEC 8-K summary
======================================

Issuer:     XBiotech Inc. (XBIT)
CIK:        0001626878
Form:       8-K
Filed at:   2022-02-02T23:59:59+00:00
Accession:  0001171843-22-000711
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

XBiotech extends clinical manufacturing agreement with Janssen through December 2023
--------------------------------------------------------------------------------

- XBiotech entered a Manufacturing Agreement with Janssen R&D to produce clinical product including Bermekimab.
- Agreement extends manufacturing support through December 2023; revenue extends cash runway for own pipeline.
- Bermekimab, a True Human monoclonal antibody, was sold to Janssen in December 2019 with transitional manufacturing.
- CEO John Simard stated contract manufacturing is not core business but fits well and provides runway for up-and-coming therapeutics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1626878/000117184322000711/0001171843-22-000711-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1626878/000117184322000711/f8k_020222.htm
  HTML page:      https://secwatch.observer/filing/0001171843-22-000711

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer